Dyslipidemia in systemic lupus erythematosus
- PMID: 28168401
- DOI: 10.1007/s12026-016-8892-9
Dyslipidemia in systemic lupus erythematosus
Abstract
Cardiovascular disease is one of the major causes of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Accelerated atherosclerosis is related to traditional (age, hypertension, diabetes mellitus, dyslipidemia, obesity, smoking, and positive family history) and non-traditional, disease-related factors. Traditional risk factors are still more prominent in patients with lupus, as both hypertension and hypercholesterinemia were independently associated with premature atherosclerosis in several SLE cohorts. In this work, the authors summarize the epidemiology of dyslipidemia in lupus patients and review the latest results in the pathogenesis of lipid abnormalities. The prevalence of dyslipidemia, with elevations in total cholesterol (TC), low-density lipoprotein (LDL), triglyceride (TG), and apolipoprotein B (ApoB), and a reduction in low-density lipoprotein (LDL) levels are about 30% at the diagnosis of SLE rising to 60% after 3 years. Multiple pathogenetic mechanism is included, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can suppress HDL and increase TG, auto-antibodies can cause the injury of the endothelium, lipoprotein lipase (LPL) activity can be reduced by circulating inflammatory mediators and antibodies, and increased oxidative stress may trigger a wide range of pro-atherogenic lipid modifications. As a major risk factor, dyslipidemia should be treated aggressively to minimize the risk of atherosclerosis and cardiovascular events. Randomized controlled trials with statins are controversial in the detention of atherosclerosis progression, but can be favorable by inhibiting immune activation that is the arterial wall and by decreasing lupus activity.
Keywords: Accelerated atherosclerosis; Dyslipidemia; Reverse cholesterol transport; Systemic lupus erythematosus.
Similar articles
-
Dyslipidemia in systemic lupus erythematosus: just another comorbidity?Semin Arthritis Rheum. 2016 Apr;45(5):604-10. doi: 10.1016/j.semarthrit.2015.10.010. Epub 2015 Oct 29. Semin Arthritis Rheum. 2016. PMID: 26711309 Review.
-
Pitavastatin: novel effects on lipid parameters.Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Atheroscler Suppl. 2011. PMID: 22152282 Review.
-
[Analysis of traditional cardiovascular risk factors in patients with systemic lupus erythematosus].Zhonghua Xin Xue Guan Bing Za Zhi. 2014 Sep;42(9):753-8. Zhonghua Xin Xue Guan Bing Za Zhi. 2014. PMID: 25511096 Chinese.
-
Management of dyslipidemia in children and adolescents with systemic lupus erythematosus.Lupus. 2007;16(8):618-26. doi: 10.1177/0961203307079566. Lupus. 2007. PMID: 17711898 Review.
-
Clinical and laboratory aspects of dyslipidemia in Brazilian women with systemic lupus erythematosus.Clin Rheumatol. 2018 Jun;37(6):1539-1546. doi: 10.1007/s10067-018-4051-0. Epub 2018 Mar 8. Clin Rheumatol. 2018. PMID: 29516281
Cited by
-
Autoimmune diseases and atherosclerotic cardiovascular disease.Nat Rev Cardiol. 2024 Nov;21(11):780-807. doi: 10.1038/s41569-024-01045-7. Epub 2024 Jun 27. Nat Rev Cardiol. 2024. PMID: 38937626 Review.
-
Medicinal Plant Extracts and Natural Compounds for the Treatment of Cutaneous Lupus Erythematosus: A Systematic Review.Front Pharmacol. 2022 Mar 31;13:802624. doi: 10.3389/fphar.2022.802624. eCollection 2022. Front Pharmacol. 2022. PMID: 35431950 Free PMC article.
-
SARS-CoV-2 induced HDL dysfunction may affect the host's response to and recovery from COVID-19.Immun Inflamm Dis. 2023 May;11(5):e861. doi: 10.1002/iid3.861. Immun Inflamm Dis. 2023. PMID: 37249296 Free PMC article. Review.
-
Modern therapy of patients with lupus erythematosus must include appropriate management of their heightened rates of atherosclerotic cardiovascular events: a literature update.Lupus Sci Med. 2025 Apr 8;12(1):e001160. doi: 10.1136/lupus-2024-001160. Lupus Sci Med. 2025. PMID: 40204295 Free PMC article. Review.
-
CRP Serum Levels Are Associated with High Cardiometabolic Risk and Clinical Disease Activity in Systemic Lupus Erythematosus Patients.J Clin Med. 2022 Mar 26;11(7):1849. doi: 10.3390/jcm11071849. J Clin Med. 2022. PMID: 35407457 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous